These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8299365)

  • 1. Side effects of topical glucocorticoids.
    Mills CM; Marks R
    Curr Probl Dermatol; 1993; 21():122-31. PubMed ID: 8299365
    [No Abstract]   [Full Text] [Related]  

  • 2. Topical glucocorticoids and thinning of normal skin as to be assessed by ultrasound.
    Korting HC
    Curr Probl Dermatol; 1993; 21():114-21. PubMed ID: 8299364
    [No Abstract]   [Full Text] [Related]  

  • 3. Influence of glucocorticoid substances and the vehicle on skin irritancy: determination by profilometry.
    Korting HC
    Curr Probl Dermatol; 1993; 21():140-6. PubMed ID: 8299367
    [No Abstract]   [Full Text] [Related]  

  • 4. 0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream.
    Korting HC; Vieluf D; Kerscher M
    Eur J Clin Pharmacol; 1992; 42(2):159-61. PubMed ID: 1618247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local tolerability of topically applied methylprednisolone aceponate.
    Kecskés A; Jahn P; Lange L
    J Am Acad Dermatol; 1993 May; 28(5 Pt 1):786-8. PubMed ID: 8496430
    [No Abstract]   [Full Text] [Related]  

  • 6. Early detection of glucocorticoid-specific epidermal alterations using skin surface microscopy.
    Schulz H; Nietsch KH; Höhler T
    Curr Probl Dermatol; 1993; 21():132-9. PubMed ID: 8299366
    [No Abstract]   [Full Text] [Related]  

  • 7. Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo.
    Serup J; Holm P
    Dermatologica; 1985; 170(4):189-94. PubMed ID: 3888708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are the Spanish baseline series markers sufficient to detect contact allergy to corticosteroids in Spain? A GEIDAC prospective study.
    Mercader-García P; Pastor-Nieto MA; García-Doval I; Giménez-Arnau A; González-Pérez R; Fernández-Redondo V; Serra-Baldrich E; Cordoba-Guijarro S; Gatica-Ortega ME; Silvestre-Salvador JF;
    Contact Dermatitis; 2018 Jan; 78(1):76-82. PubMed ID: 28960334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of induced inflammation in man.
    Kerscher MJ
    Curr Probl Dermatol; 1993; 21():97-106. PubMed ID: 8299382
    [No Abstract]   [Full Text] [Related]  

  • 10. Topical glucocorticoids of the non-fluorinated double-ester type. Lack of atrophogenicity in normal skin as assessed by high-frequency ultrasound.
    Kerscher MJ; Korting HC
    Acta Derm Venereol; 1992; 72(3):214-6. PubMed ID: 1357864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry; a double-blind, placebo-controlled trial.
    Cossmann M; Welzel J
    Br J Dermatol; 2006 Oct; 155(4):700-6. PubMed ID: 16965418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of segmental vitiligo to 0.05% clobetasol propionate cream.
    Khalid M; Mujtaba G
    Int J Dermatol; 1998 Sep; 37(9):705-8. PubMed ID: 9762827
    [No Abstract]   [Full Text] [Related]  

  • 13. [Risk of atrophy induced by recent topical glucocorticoids].
    Niedner R
    Hautarzt; 1995 Nov; 46(11):812. PubMed ID: 8641891
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of the effects of calcipotriol, prednicarbate and clobetasol 17-propionate on normal skin assessed by ultrasound measurement of skin thickness.
    Lévy J; Gassmüller J; Schröder G; Audring H; Sönnichsen N
    Skin Pharmacol; 1994; 7(4):231-6. PubMed ID: 8024805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo determination of the skin atrophy potential of the super-high-potency topical corticosteroid fluocinonide 0.1% cream compared with clobetasol propionate 0.05% cream and foam, and a vehicle.
    Gans EH; Sadiq I; Stoudemayer T; Stoudemayer M; Kligman AM
    J Drugs Dermatol; 2008 Jan; 7(1):28-32. PubMed ID: 18246695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic effects of topically applied methylprednisolone aceponate in healthy volunteers.
    Kecskés A; Jahn P; Matthes H; Kuhlmann RK; Lange L
    J Am Acad Dermatol; 1993 May; 28(5 Pt 1):789-92. PubMed ID: 8496431
    [No Abstract]   [Full Text] [Related]  

  • 17. Fatal iatrogenic Cushing's syndrome.
    Nathan AW; Rose GL
    Lancet; 1979 Jan; 1(8109):207. PubMed ID: 84219
    [No Abstract]   [Full Text] [Related]  

  • 18. An open label study of clobetasol propionate 0.05% and betamethasone valerate 0.12% foams in the treatment of mild to moderate acne keloidalis.
    Callender VD; Young CM; Haverstock CL; Carroll CL; Feldman SR
    Cutis; 2005 Jun; 75(6):317-21. PubMed ID: 16047868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different skin thinning potential of equipotent medium-strength glucocorticoids.
    Korting HC; Unholzer A; Schäfer-Korting M; Tausch I; Gassmueller J; Nietsch KH
    Skin Pharmacol Appl Skin Physiol; 2002; 15(2):85-91. PubMed ID: 11867964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of corticosteroids on the growth and metabolism of fibroblasts cultured from human skin.
    Priestley GC
    Br J Dermatol; 1978 Sep; 99(3):253-61. PubMed ID: 81679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.